BNET Industries

Market Cap:$149.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Susan Kim: Menopause: Marketing Fear
-
Takeda, Pfizer To Co-Promote Actos Type 2 Diabetes Drug In China - Update
-
Pfizer Raises Quarterly Dividend 13%, See More Annual Hikes
-
REG-Pfizer Inc Pfizer Declares an 18-Cent First-Quarter 2010 Dividend
-
BRIEF: SEC probing insider-trading allegations
-
Pfizer joins partnership with Calif. firm: Collaboration planned with Crown Bioscience for cancer research
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Private security firms no longer able to provide police information checks
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Market Report -- In Play PFE
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
News & Analysis
Filter by
marketing and pfizer inc. - All News and Analysis
J&J CEO Rubs Pfizer's Face in Disastrous Consumer Products Sale of '06
Toldya: One year ago, BNET noted that Pfizer PFE must have been crazy to sell its consumer products unit to Johnson & Johnson JNJ. The deal included brands such as Nicorette, Zantac and Benadryl. J&J's Q3 earnings report showed that the consumer products unit has done much better than its...
Pfizer Tries Again for Sanctions Against Neurontin Witness
Pfizer PFE is playing hardball in its attempt to get sanctions applied to an expert in the Neurontin litigation who contacted another witness wthout the drug company's permission. The company is asking a judge to overturn the ruling of a federal magistrate that sanctions should not be applied to Dr....
Auxilium Pharmaceuticals, Inc. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Marshall Urist with Morgan Stanley. Please proceed. Marshall Urist - Morgan Stanley Yeah, hi guys, good morning. Couple of things, first one just from your comments on the – on the Pfizer, Pfizer said in...
UPDATED: What Agencies Need to Know About Pfizer's Viagra Account
Any agency pitching Pfizer's Viagra account may want to bear the following in mind: The patent on Viagra expires somewhere between June 2011 and March 2012, which is when the client will likely end its ad budget for the brand. by Jim Edwards
Actavis launches challenge to Pfizer drug
Actavis, the Iceland-based generic company, yesterday launched the most high profile commercial challenge in western Europe to Pfizer's best-selling and patentprotected medicine.The company said it had made a first shipment of 30m tablets into Spain of a cheaper variant of Lipitor, known generically as atorvastatin, which is widely prescribed...
Pfizer Rep Alleges Viagra Promoted With Unapproved Materials: "Get Those Things Cleaned Up!"
Blair Collins, a former Pfizer sales rep who received $2.4 million as one of the whistleblowers in the $2.3 billion Bextra settlement, alleged that reps used unapproved studies and pricing sheets to promote Viagra, among other drugs. by Jim Edwards
Pfizer Faces $21 Billion in Fines for Pharmacia's Crimes; 32 Other Companies on the Hook
A jury verdict in Wisconsin could expose Pfizer to up to $21 billion in fines after the company was found guilty of gaming Medicaid. It will likely prompt a wave of settlements from other drug companies that are on the hook in this raft of cases. Pfizer,...
Pfizer Asks Media Members: How Are We Doing?
Pfizer is polling about 250 members of the media to find out whether its PR operations are any good. The move appears to be part of Pfizer PR chief Ray Kerins' drive to change Pfizer's image from a Kremlin-esque castle of puzzles into a more communicative, forthright enterprise. ...
Pfizer Ends Its "Unwritten Rule": Don't Return Reporters' Calls
Pfizer pr chief Ray Kerins said that Pfizer had an "unwritten rule" for dealing with the media: Don't return reporters' calls. Here's what Ad Age says he told the Business Development Institute's Real-Time Communications Conference: Back in 2007, on the second day of his new job as Pfizer's global...
Pfizer Paid Medical Director for State-Funded Anti-Smoking Campaign
UPDATE: The doctor at the center of the report says his roll was misrepresented, and that there was no overlap between his time at Pfizer and the anti-smoking project he later led. See comments section below for full statement. The medical director of a state-funded anti-smoking project...
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
